Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, Share & Trends Analysis, By Type (Mild, Moderate), By Drug Class (Antacids, Proton Pump Inhibitors, Histamine Blockers), By Distribution Channel, By Region and Forecast Period 2023 – 2030 (Updated Version Available)

Report ID - MRC_4077 | Pages - 216 | Category - Healthcare and Pharma

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Insights:

The Gastroesophageal Reflux Disease (GERD) Therapeutics Market size was valued at USD 5.17 Billion in 2022, expecting a CAGR of 1.75% during the forecast period (2023-2030), and the market is projected to be worth USD 5.94 Billion by 2030.

Driver:

The increased adoption of Gastroesophageal Reflux Disease (GERD) Therapeutics in the Pharmaceuticals industry is due to high workability, Stability of structure, good quality, and Demand for making things better. The demand for Gastroesophageal Reflux Disease (GERD) Therapeutics also has other significant aspects, such as analysis, purchasing volume, costs, pricing analysis, and regulatory framework. Additionally, the increased demand of Gastroesophageal Reflux Disease (GERD) Therapeutics in many sectors also boosts the market growth during the forecast period.

Gastroesophageal reflux disease (GERD) therapeutics refer to the various treatments and medications used to manage the symptoms of GERD, a digestive disorder that occurs when stomach acid or bile flows back into the esophagus, causing irritation and inflammation. GERD therapeutics include lifestyle changes, over-the-counter medications, prescription medications, and surgery. Lifestyle changes may include avoiding trigger foods, losing weight, elevating the head of the bed, and avoiding eating before bedtime.

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Research Report” was just released by Market Research Community. It is divided into several categories, including By Type (Mild, Moderate, Severe), By Drug Class (Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and companies (AstraZeneca, Eisai Co. Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals Inc., Camber Pharmaceuticals Inc), According to the analysis of Market Research Community, The market is projected to grow at a significant pace reaching a CAGR of approximately 1.75%, over the forecast period of 2023–2030.

Report Coverage:

Report Attributes Report Details
Study Timeline 2017-2030
Market Size in 2030 (USD Billion) 5.94 Billion
CAGR (2023-2030) 1.75%
By Type      Mild, Moderate, Severe
By Drug Class Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Others
By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
By Geography North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Key Players AstraZeneca, Eisai Co. Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals Inc., Camber Pharmaceuticals Inc.

Get Free Sample PDF

Covid-19 Impact:

The COVID-19 pandemic has had a substantial negative influence on the Gastroesophageal Reflux Disease (GERD) Therapeutics market in many different regions of the world. The factors such as limited availability of raw materials, transportation restrictions, the shutdown of manufacturing facilities, and economic slowdown are the major impacts of COVID-19 which hampered the market growth. Shipments were impacted during the initial lockdown due to halted automotive productions and stringent government rules. The overall impact of COVID-19 on the industry is estimated to be minimal because the situation has stabilised. Post covid-19, there was a positive impact on the market growth due to the increased industrial manufacturing processes and rising demand for environment-friendly alternatives.

Industry Competitive Landscape:

The research includes comprehensive profiles of the key players in the market and an analysis of the competitive landscape. The market for sample preparation has grown more quickly as a result of the spike in research and development (R&D), product innovation, different business strategies, and application releases. Key players in the market include-

AstraZeneca, Eisai Co. Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals Inc., Camber Pharmaceuticals Inc.

Market Segment Analysis:

By Type

  • Mild
  • Moderate
  • Severe

By Drug Class

  • Antacids
  • Proton Pump Inhibitors
  • Histamine Blockers
  • Pro-Kinetic Agents
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Region

The regional segment includes Asia Pacific, Europe, North America, the Middle East, and Africa, Latin America. In 2022, some of these regions expected to contribute the largest share during the forecast period.

The factors such as the large and easy availability of basic things, rising purchasing power among the population, and favorable government policies and industrial facilities are estimated to accelerate the industry growth in the region. The growing rate of industrialization is anticipated to boost the presence of Gastroesophageal Reflux Disease (GERD) Therapeutics industries in the region.

Key Gastroesophageal Reflux Disease (GERD) Therapeutics Market Trends

– Based on type, sub-type, technology utilised, applications, end-users, and geographies, the research identifies, defines, and predicts the Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market segments.

– Largest Market Share Held by Industry to Industry for Gastroesophageal Reflux Disease (GERD) Therapeutics

– Based on their expected growth, development patterns and prospects for the future, and contributions to the overall market, it analyses the micro markets.

– Demand from the geographical area is estimated to boost growth.

– Growing Market Segment Adoption in the Gastroesophageal Reflux Disease (GERD) Therapeutics Industry

– Over the forecast period, higher growth rates are anticipated in in some regions

Why Purchase the Industry Report by MRC

There is a huge amount of information in the report, including market trends and business opportunities for the forecast period.

Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) statistics.

Data at the regional, sub-regional, and national levels also includes information on the market’s supply and demand dynamics.

The competitive landscape includes the proportions of important players, recent innovations, and strategy.

Comprehensive product offerings, important financial data, latest advancements, SWOT analysis, and key player tactics.

Table of Content

To check our Table of Contents, please mail us at: [email protected]

Research Methodology

The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.

Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, Share & Trends Analysis, By Type (Mild, Moderate), By Drug Class (Antacids, Proton Pump Inhibitors, Histamine Blockers), By Distribution Channel, By Region and Forecast Period 2023 – 2030 (Updated Version Available)
Back to top button